Important Update for Investors in Outset Medical
Levi & Korsinsky, LLP has issued a critical notification for those invested in Outset Medical, Inc. This comes in light of a class action securities lawsuit that could significantly affect shareholders. Outset Medical is known for its innovative dialysis care solutions, with the stock ticker OM.
What’s the Class Action Lawsuit About?
The purpose of this class action lawsuit is to recover losses suffered by investors who may have been harmed by alleged securities fraud. The period in question includes claims made from August 1, 2022, to August 7, 2024. The lawsuit aims to address potential financial damages that shareholders could have experienced during this timeframe.
What Are the Allegations Against Outset Medical?
Investors deserve transparency concerning the allegations at the heart of this lawsuit. The complaint states that several false statements were made or key facts were withheld. Specifically, there are claims that the Tablo products, the company's main devices for dialysis, were marketed in ways that didn't match FDA-approved uses.
Additionally, there are suggestions that Outset Medical may need to submit further applications for their products to meet market requirements. This uncertainty could seriously affect the company's sales strategy, as there are indications that resources might not be enough to support a ramp-up in sales for these devices. Such developments could adversely impact overall revenue growth and misrepresent the company's true condition to investors.
What Should Investors Do?
If you believe you've experienced losses during the period mentioned, it's crucial to take action quickly. Investors have until October 28, 2024, to declare their interest in being appointed as lead plaintiff in this case. However, it’s important to note that you don’t have to be a lead plaintiff to potentially benefit from any recovery.
Cost of Legal Fees and Participation
A key point about this class action lawsuit is that there are no upfront costs for class members. Investors can come forward without worrying about financial burdens, as they may qualify for compensation without any out-of-pocket expenses. This adds a layer of security for those who have been negatively impacted.
Why Opt for Levi & Korsinsky?
Levi & Korsinsky brings over 20 years of impressive experience, having recovered hundreds of millions for shareholders. The firm specializes in complex securities litigation and has a dedicated team of more than 70 professionals focused on client needs.
Consistently ranked in the ISS Securities Class Action Services' Top 50 Report as one of the top firms for securities litigation in the United States, Levi & Korsinsky shows its commitment to advocating vigorously for investors.
Contact Details
If you need further information or wish to discuss your situation, consider reaching out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit addresses alleged securities fraud impacting investors of Outset Medical, aiming to recover financial losses during a specific period.
How can I participate in the lawsuit?
Investors should express their interest in joining before the deadline of October 28, 2024.
What costs are involved in joining the class action?
There are no upfront costs for those who choose to participate in the class action lawsuit.
Can I recover even if I am not a lead plaintiff?
Yes, you can still receive damages even if you’re not a lead plaintiff.
Why should I choose Levi & Korsinsky?
The firm has a solid track record in securities litigation, with significant expertise and a history of securing substantial recoveries for its clients.
